Rizine Mzikamanda

Rizine Mzikamanda

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
DHDavid M. Holmes
David M. Holmes
AMApatsa Matatiyo
Apatsa Matatiyo
AMAtupele Mpasa
Atupele Mpasa
MHMinke H. W. Huibers
Minke H. W. Huibers
GMGeoffrey Manda
Geoffrey Manda
CMCasey McAtee
Casey McAtee

1 February 2025 in JCO Global Oncology
Verified
Journal Article
Open access
DNDavid Noyd
David Noyd
AIAna Carolina Izurieta-Pacheco
Ana Carolina Izurieta-Pacheco
RMRizine Mzikamanda
Rizine Mzikamanda
NNNana Nakiddu
Nana Nakiddu
DADao Thi Thanh An
Dao Thi Thanh An
SFSoad Fuentes-Alabí
Soad Fuentes-Alabí
The WHO Global Initiative for Childhood Cancer, prompted by the marked inequity of survival across the globe, aims to increase survival rates in low- and middle-income countries to 60% by 2030. In tandem with this effort, implementing survivorship-focused care is crucial to mitigate late effects and prevent early mortality beyond the 5-year survival end point. The observed burden of secondary malignancies, cardiovascular disease, and other chronic health conditions in adult survivors of childhood cancer in high-income countries provides guidance to generate evidence in limited-resource settings. The implementation of risk stratification tools, population health management, and development of contextually relevant health care delivery models, within the current landscape of survivorship care in Latin America, Africa, and Asia as examples, are vital to continue the momentum to ensure equitable care and quality of life for all survivors of childhood cancer. This narrative review informed by expert opinion serves as a call to action for survivors, advocacy groups, health professionals, health systems, governments, and global organizations to look beyond the 5-year survival benchmark.

22 November 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
CCCarolina Caro-Vegas
Carolina Caro-Vegas
APAlice Peng
Alice Peng
AJAngelica Juarez
Angelica Juarez
ASAllison Silverstein
Allison Silverstein
WKWilliam Kamiyango
William Kamiyango
NENader Kim El-Mallawany
Nader Kim El-Mallawany
BACKGROUND: Kaposi sarcoma (KS) is among the most common childhood cancers in Eastern and Central Africa. Pediatric KS has a distinctive clinical presentation compared with adult KS, which includes a tendency for primary lymph node involvement, a considerable proportion of patients lacking cutaneous lesions, and a potential for fulminant disease. The molecular mechanisms or correlates for these disease features are unknown. METHODS: This was a cross-sectional study. All cases were confirmed by IHC for KS-associated herpesvirus (KSHV) LANA protein. Baseline blood samples were profiled for HIV and KSHV genome copy numbers by qPCR and secreted cytokines by ELISA. Biopsies were characterized for viral and human transcription, and KSHV genomes were determined when possible. RESULTS: Seventy participants with pediatric KS were enrolled between June 2013 and August 2019 in Malawi and compared with adult patients with KS. They exhibited high KSHV genome copy numbers and IL-6/IL-10 levels. Four biopsies (16%) had a viral transcription pattern consistent with lytic viral replication. CONCLUSION: The unique features of pediatric KS may contribute to the specific clinical manifestations and may direct future treatment options. FUNDING: US National Institutes of Health U54-CA-254569, PO1-CA019014, U54-CA254564, RO1-CA23958.

10 January 2023 in HIV Medicine
Verified
Journal Article
Closed access
Liane CampbellLiane Campbell
Liane Campbell
ASAllison Silverstein
Allison Silverstein
EPErin Peckham
Erin Peckham
WKWilliam Kamiyango
William Kamiyango
JVJimmy Ba Villiera
Jimmy Ba Villiera
NENader Kim El-Mallawany
Nader Kim El-Mallawany

1 March 2025 in JCO Global Oncology
Verified
Journal Article
Open access
RMRizine Mzikamanda
Rizine Mzikamanda
LMLoviisa Mulanje
Loviisa Mulanje
CMCasey McAtee
Casey McAtee
AMApatsa Matatiyo
Apatsa Matatiyo
ZMZoe Mwale
Zoe Mwale
NONmazuo W. Ozuah
Nmazuo W. Ozuah
PURPOSE: Excellent survival for advanced (stages II with high lactate dehydrogenase, III, and IV) pediatric mature B-cell non-Hodgkin lymphoma (MB-NHL) has been achieved with intensive regimens, but adoption in sub-Saharan Africa is limited by inadequate supportive care. We provide real-world data on treating advanced MB-NHL with high-dose methotrexate (HD-MTX; ≥1,000 mg/m 2 /cycle) where real-time serum MTX monitoring is unavailable. METHODS: We identified two cohorts—a retrospective (January 2017-December 2020) cohort treated with 1,000 or 3,000 mg/m 2 /cycle of HD-MTX and a prospective (July 2022-July 2023) cohort—with a modified LMB96 protocol containing 3,000 mg/m 2 /cycle of HD-MTX. All doses of HD-MTX were given over 3 hours. Estimates of 12-month event-free survival (EFS) and overall survival (OS) were calculated with abandonment as an event. Clinical toxicity data were available for the prospective cohort. RESULTS: The retrospective cohort had 108 patients who received HD-MTX 1,000 mg/m 2 (n = 98, 91%) or 3,000 mg/m 2 per cycle. The 12-month EFS and OS were 39% (95% CI, 30 to 50) and 54% (95% CI, 44 to 64), respectively. HD-MTX at 3,000 mg/m 2 had superior EFS: 69% (95% CI, 49 to 96) versus 33% (95% CI, 24 to 46), P = .004. The prospective cohort had 38 patients. Two ≥grade 3 mucositis, one acute kidney injury, and three treatment-related deaths (8%) occurred. Seven (18%) abandoned treatment. With a median follow-up of 14.5 months, 12-month EFS and OS were 45% (95% CI, 32 to 65) and 59% (95% CI, 45 to 79), respectively. Most relapses were stage IV: EFS 20% versus 51% (non–stage IV; P = .057). Severe malnutrition was associated with OS of 33% versus 58% (normal) or 76% (moderate; P = .055). CONCLUSION: HD-MTX dosed at 3,000 mg/m 2 /cycle is feasible in low-resource settings where routine MTX monitoring is unavailable. Stage IV disease and severe malnutrition may contribute to poorer outcomes.

5 August 2024 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
ETE. Tembo
E. Tembo
KKK.A. Kyei
K.A. Kyei
FTFabiano Gibson Daud Thulu
Fabiano Gibson Daud Thulu
LML. Masamba
L. Masamba
JCJ. Chiwanda
J. Chiwanda
SNS. Ndarukwa
S. Ndarukwa
Radiotherapy (RT) is one of the three pillars of cancer treatment (with surgery and systemic therapies) and has proven to be a cost-effective modality for curative and palliative treatment. In low and middle-income countries, access to RT treatment is limited posing many challenges to patients and caregivers. Many patients living in low and middle-income countries (LMICs) such as Malawi spend enormous sums of money to be treated abroad, through Government schemes, or, more commonly, go without treatment. This paper reviews the progress of the Malawi Government in establishing the first dedicated cancer treatment center with RT facilities at Kamuzu Central Hospital in Lilongwe. Malawi is expected to have a fully functional dedicated RT centre towards the end of 2024 equipped with one cobalt machine, two linear accelerators (LINAC), and a high dose rate (HDR) Brachytherapy unit. More cancer patients will have access to RT services locally, resulting in the Government saving on the foreign currency required to treat patients out of the country. While there has been great progress towards establishment of services in Malawi, careful and strategic planning is needed for the sustainability of required resources to avoid long-term disruption of treatments.